Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1563 - A randomized phase II study of Maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced Pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM – PRODIGE 63 GERCOR study)


29 Sep 2019


Poster Display session 2


Tumour Site

Pancreatic Adenocarcinoma


Cindy Neuzillet


Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247


C. Neuzillet1, V. Hautefeuille2, A. Lambert3, M. Garcia-Larnicol4, D. Vernerey5

Author affiliations

  • 1 Medical Oncology, Curie institute, 92210 - Saint Cloud/FR
  • 2 Gastroenterology And Digestive Oncology, CHU Amiens-Picardie Site Nord, 80054 - Amiens/FR
  • 3 Medical Oncology, Institut de Cancérologie de Lorraine, 54519 - Vandoeuvre Les Nancy/FR
  • 4 Gercor, GERCOR, 75011 - Paris/FR
  • 5 Methodology And Quality Of Life Unit In Oncology (umqvc), University Hospital of Besançon, 25000 - Besançon/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1563


FOLFIRINOX (5FU, folinic acid [FA], irinotecan [Iri], oxaliplatin [Ox]) is a 1st-line standard in fit Pts with aPDAC. Anti-PD-(L)1 as single agents have failed in aPDAC and new combination immunotherapies are needed. Tedopi (OSE2101) is a multiple neoepitope vaccine restricted to HLA-A2 positive Pts targeting 5 tumor-associated antigens (ACE, HER2, MAGE2, MAGE3, TP53) frequently expressed in PDAC. This study aims to assess the efficacy and safety of Tedopi alone and in combination with anti-PD-1 nivolumab or FOLFIRI as maintenance therapy in aPDAC Pts after FOLFIRINOX induction CT.

Trial design

TEDOPaM is a 3-arm, Fleming 2-stage, open-label, randomized, non-comparative phase II study. 156 Pts with recurrent or advanced, pathologically proven PDAC; ECOG PS 0-1; HLA-A2 genotype; controlled disease (PR or SD) after 8 cycles of FOLFIRINOX; adequate organ functions, are randomized (1:1:1, stratified on center, tumor stage, best response to FOLFIRINOX) into 3 arms:Table:


Arm A (reference): FOLFIRI (n = 52)IV; FA 400 mg/m2, Iri 180 mg/m2, 5FU bolus 400 mg/m2 + continuous 2400 mg/m2/46h
Arm B: Tedopi (n = 52)Subcutaneous injection on D1 Q3W/6 doses then Q8W until month 12 [M12] then Q12W up to M24
Arm C: Tedopi + nivolumab (n = 52)Tedopi + nivolumab 360 mg IV on D1 Q3W/6 doses then 480 mg Q4W up to M24

In Arms B and C, reintroduction of FOLFIRI at disease progression or unacceptable toxicity. Primary endpoint: overall survival rate at M12. Secondary: progression-free survival (CT-scan Q8W), duration of disease control, safety, response rate, RECIST v1.1/iRECIST comparison, HRQoL, Q-TWiST. Interim analysis after inclusion of 20 Pts in each arm. Translational research on tumor tissue (initial FFPE biopsy and optional re-biopsy at inclusion): RNAseq (cancer and stroma), mutation burden, MMR status, immune infiltrates; and in blood (before and on-treatment): cytokine panel, PBMC phenotyping, vaccine-antigen specific T-cells, TCR repertoire, extracellular vesicles to explore biomarkers and pharmacodynamics effects of Tedopi ± nivolumab.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study



OSE Immunotherapeutics.


C. Neuzillet: Honoraria (self), Not related to the abstract: Amgen; Honoraria (self), Not related to the abstract: AstraZeneca; Research grant / Funding (institution), Not related to the abstract: Celgene; Honoraria (self), Travel / Accommodation / Expenses, Not related to the abstract: MSD; Research grant / Funding (institution), Travel / Accommodation / Expenses, PI of the TEDOPaM Clinical Trial: OSE Immunotherapeutics; Honoraria (self), Not related to the abstract: Roche; Honoraria (self), Not related to the abstract: Servier. V. Hautefeuille: Honoraria (self), Not related to the abstract: Amgen; Honoraria (self), Not related to the abstract: Novartis; Honoraria (self), Not related to the abstract: Ipsen; Honoraria (self), Not related to the abstract: Pfizer; Honoraria (self), Not related to the abstract: AAA; Honoraria (self), Not related to the abstract: Sanofi; Honoraria (self), Not related to the abstract: Merck; Honoraria (self), Not related to the abstract: Servier; Honoraria (self), Not related to the abstract: Lilly. A. Lambert: Advisory / Consultancy: Janssen; Advisory / Consultancy: Merck KGaA; Advisory / Consultancy: Bayer; Honoraria (self): Servier/Pfizer. D. Vernerey: Advisory / Consultancy: OSE Immunotherapeutics; Advisory / Consultancy: HalioDX; Advisory / Consultancy: Pfizer; Advisory / Consultancy: CellProthera. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.